BALANCED INVESTMENT TO ADVANCE OUR BUSINESS
Vertex aspires to become a fully capable biopharmaceutical company – one capable of discovering, developing and marketing multiple breakthrough products that may improve the lives of patients and deliver value to our shareholders.

Today, Vertex has a unique set of product opportunities in various diseases to help define our future success. The planned submission of the New Drug Application for telaprevir in the second half of 2010 is our top priority. As the Phase 3 registration program for telaprevir nears completion, our 2010 investment in telaprevir will be focused on critical pre-launch activities, including the expansion of our commercial supply and the implementation of key elements of the infrastructure needed to support Vertex's first sales force. We are balancing investments across our business to ensure telaprevir's commercial success.

Beyond HCV, we are also strengthening our focus on novel approaches to other specialty disease areas, such as cystic fibrosis, and we continue to support our innovative research capabilities. We believe that cutting-edge science leads to future breakthrough products, and thus we will invest in the necessary areas of our business to support continued advancement toward becoming a fully capable biopharmaceutical company.

Vertex began 2010 with a cash position of approximately $1.3 billion and, as of early 2010, had no outstanding convertible debt – a strong capital structure that creates flexibility as our business continues to grow in today's uncertain economic and industry environment.

At Vertex, innovation is not a corporate maxim; it's our lifeblood.

These data are derived from our consolidated financial statements. Our audited consolidated financial statements, including the related footnotes and "Management's Discussion and Analysis of Financial Condition and Result of Operations," are included in our 2009 Annual Report on Form 10-K.
These materials include forward-looking statements; please refer to the Safe Harbor statement on the accompanying annual report.